Molecular Partners AG (MLLCF)
Develops protein-based cancer drugs using engineered molecules to attack tumors
$3.80+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-10.0%
The outlook
MLLCF is trading roughly midway through its 52-week range after a mixed recent trend against its moving averages. Analyst coverage appears thin on this stock. The current data leans slightly bullish overall, though the price action remains relatively flat today.
What’s behind the score
Price trendMixed vs its moving averages
52-week range60% of the way from its 52-week low to high
Market cap
$142.5M
52-wk high
$4.85
52-wk low
$2.25
50-day avg
$3.92
200-day avg
$3.23
Trailing P/E
—